Understanding the Role of Magnesium for Myeloma Patients | Urvi Shah, MD | #ASH24

Daratumumab for Patient with High-risk Smoldering Myeloma | Rahul Banerjee | #ASH24

Improving MGUS Care through Collaborative Models and Community-Based Support | Beth Faiman, CNP, PhD | #ASH24

Talquetamab in Myeloma: Results from HealthTree Qualitative Research | Beth Faiman, CNP, PhD | #ASH24

Late Complications and Long-term Care of CAR T-cell Patients | Michael Bishop, MD | #ASH24

Phase 1 Study of Antio-cel, an Anti-BCMA CAR-T, for RRMM | Michael Bishop, MD | #ASH24

The Unique Power of Whole Genome Sequencing in Multiple Myeloma | Francesco Maura, MD | #ASH24

Anti-BCMA CAR-T Resistance in Myeloma: Genomic Predictors | Francesco Maura, MD | #ASH24

Tri-specific Antibody SAR442257 in RRMM and Non-Hodgkin Lymphoma | Fredrik Schjesvold, MD, PhD | #ASH24

Daratumumab vs Observation in High-Risk SMM (Aquila Study) | Meletios Dimopoulos, MD | #ASH24

Improvement of Outcomes in High-risk Myeloma (Optimum/Muknine Trial) | Martin Kaiser | #ASH24

Management and Outcomes of MGRS (Monoclonal Gammopathy of Renal Significance) | Danai Dima | #ASH24

Outcomes of Teclistamab in RRMM Patients Who Had Prior BCMA-Directed Therapy | Danai Dima | #ASH24

Belentamab Plus Cyclophosphamide & Dexamethasone in RRMM (ProMMise Study) | Rakesh Popat | #ASH24

MRD Results from Cartitude-4 (Cilta-Cel vs SOC) in RRMM | Rakesh Popat | #ASH24

Delayed Neutrophil Recovery Following BCMA-Directed CAR-T in Myeloma | Zachary Avigan, MD | #ASH24

Using whole genome sequencing to differentiate between low-risk and high-risk smoldering myeloma | Mehmet Samur, PhD | #ASH24

Genomic Determinants of Resistance to Anti-BCMA CAR-T Therapies in Myeloma | Ciara Freeman | #ASH24

Anito-Cel, a novel anti-BCMA CAR T-cell, for Relapsed/Refractory Myeloma | Ciara Freeman, MD | #ASH24

Ethnic Disparities in Myeloma Outcomes | Muzaffar Qazilbash, MD | #ASH24

Comparing Outcomes in Younger Multiple Myeloma Patients | Marc Braunstein, MD, PhD | #ASH24

Demonstrating Better Protection with 3 Flu Shots in Myeloma | Craig Hofmeister, MD, MPH | #ASH24

High-Fiber NUTRIVENTION Study for Delaying Progression of Myeloma | Urvi Shah, MD | #ASH24